Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telisotuzumab adizutecan - AbbVie

Next Previous
Drug Profile

Telisotuzumab adizutecan - AbbVie

Alternative Names: ABBV-400; Temab-A

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Adenocarcinoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Solid tumours
  • No development reported Gastric cancer; Oesophageal cancer

Most Recent Events

  • 12 Sep 2025 AbbVie plans a phase II trial for Colorectal Cancer (Metastatic disease, Combination therapy) in
  • 04 Sep 2025 AbbVie plans a phase II/III trial for Non-small cell lung cancer (Late stage disease, Metastatic disease, Second line therapy or greater) (IV, infusion) in November 2025 (NCT07155187)
  • 07 Aug 2025 Phase-II clinical trials in Colorectal cancer (Monotherapy) in Taiwan, USA (IV) (NCT07023289)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top